CMBA
VERV

C.M. Bidwell & Associates’s Verve Therapeutics VERV Stock Holding History

C.M. Bidwell & Associates’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-101
Closed -$1.34K – 574
2023
Q3 		$1.34K Hold
101
– – ﹤0.01% 496
2023
Q2 		$1.89K Hold
101
– – ﹤0.01% 474
2023
Q1 		$1.46K Hold
101
– – ﹤0.01% 485
2022
Q4 		$1.95K Buy
+101
New +$2.68K ﹤0.01% 456

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

C.M. Bidwell & Associates's VERV Position: Q4 2023 in Review

C.M. Bidwell & Associates sold out of Verve Therapeutics (VERV) in Q4 2023, closing a stake of 101 shares — an estimated $1.34K sold.

C.M. Bidwell & Associates first reported a position in VERV in Q4 2022 and held it in 4 quarters. The position peaked at $1.95K in Q4 2022. 157 funds tracked by Wall St. Rank hold VERV as of Q4 2023.

  • C.M. Bidwell & Associates reported no remaining Verve Therapeutics position as of Q4 2023 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 101 Verve Therapeutics shares in Q4 2023, an estimated $1.34K.
  • C.M. Bidwell & Associates first reported a position in Verve Therapeutics in Q4 2022 and held it in 4 quarters.
  • C.M. Bidwell & Associates's Verve Therapeutics position peaked at $1.95K in Q4 2022.
  • 157 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2023.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2023, filed 14 Feb 2024.